Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with coexistence of factor II and MTHFR mutations [14]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 1111-

  Shamseddine, A I ^a   Otrock, Z K ^a   Mahfouz, R A R ^a   Makarem, J A ^a   Taher, A T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HEPARIN; PROTHROMBIN; WARFARIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD);

ADULT; ANAMNESIS; ASCITES; BUDD CHIARI SYNDROME; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; GENOTYPE; HEPATOSPLENOMEGALY; HUMAN; INCIDENCE; LETTER; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VEIN THROMBOSIS; GENETICS; HEMOGLOBINURIA; HETEROZYGOTE; INTERNATIONAL NORMALIZED RATIO; LIVER VEIN THROMBOSIS; MUTATION; RADIOGRAPHY; SPLEEN; THROMBOPHILIA; TIME;

ADULT; ASCITES; FACTOR V; HEMOGLOBINURIA; HEMOGLOBINURIA, PAROXYSMAL; HEPATIC VEIN THROMBOSIS; HETEROZYGOTE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); MUTATION; PROTHROMBIN; SPLEEN; THROMBOPHILIA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; WARFARIN;

EID: 23844473045     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01283.x     Document Type: Letter

References (7)

1. Rotoli B, Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Baillieres Clin Haematol 1989; 2: 113-38.
2. Smith LJ. Paroxysmal nocturnal hemoglobinuria. Clin Lab Sci 2004; 17: 172-7.
3. Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-8.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
5. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
6. Taher A, Khalil I, Abou-Merhi R, Shamseddine A, Bazarbachi A. High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon. Thromb Haemost 2003; 89: 945-6.
7. Almawi WY, Finan RR, Tamim H, Daccache JL, Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am J Hematol 2004; 76: 85-7.